#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
|
|
- Bruce Caldwell
- 5 years ago
- Views:
Transcription
1 #CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by
2 Pediatric Bipolar Disorder: Diagnosis and Management Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston, TX
3 Karen Dineen Wagner, MD, PhD Disclosures (Past 12 Months) Honoraria: UBM Medica LLC; American Society of Clinical Psychopharmacology (ASCP)
4 Off-Label Use Medications discussed in this presentation are off-label for the treatment of bipolar I disorder, manic or mixed episodes in youth, with the exception of lithium, aripiprazole, quetiapine, risperidone, olanzapine and asenapine.
5 Screening for Adolescent Bipolar Disorder
6 Mood Disorder Questionnaire- Adolescent Version (MDQ-A) Screening Criteria 5/13 Symptoms from Question 1 1. Has there ever been a time for a week or more when your adolescent was not his/her usual self and YES NO felt too good or excited? was so irritable that he/she started fights or arguments with people? felt he/she could do anything? needed much less sleep? couldn t slow his/her mind down or thoughts raced through his/her head? was so easily distracted by things? had much more energy than usual? was much more active or did more things than usual? Wagner KD et al. J Clin Psychiatry. 2006;67(5):
7 Mood Disorder Questionnaire- Adolescent Version (continued) had many boyfriends or girlfriends at the same time? Yes on Question 2 was more interested in sex than usual? did many things that were foolish or risky? spent too much money? used more alcohol or drugs? 2. If you checked YES to more than one of the above, have several of these ever happened to your adolescent during the same period of time? Moderate or Serious on Question 3 3. How much of problems did any of these cause your adolescent like school problems, failing grades, problems with family and friends, legal troubles? Please circle one response only. No problem Minor problem Moderate problem Serious problem Wagner KD et al. J Clin Psychiatry. 2006;67(5):
8 Diagnosis of Pediatric Bipolar Disorder
9 Bipolar I Disorder DSM-5 Criteria Manic Episode Elevated, expansive, irritable mood for 1 week (any duration if hospitalized) AND Increased goal-directed activity or energy Three or more symptoms (four if mood is only irritable) Inflated self esteem, grandiosity Decreased need for sleep Talkative, pressured speech Flight of ideas, racing thoughts Distractibility Impairment or hospitalization American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed
10 Course of Pediatric Bipolar Disorder
11 8-Year Follow-up of Children with Bipolar I Disorder Cumulative*Frequency*of* Recovery*from*First*Manic* Episode Baseline: N = 115 children, mean age Follow%Up((years) Geller B, et al. Arch Gen Psychiatry. 2008;65(10): Recovery Rate 88%
12 Eight Year Follow-up of Children with Bipolar I Disorder By young adulthood: 44% had manic episodes 20% had depressive episodes 35% had substance use disorders Geller B, et al. Arch Gen Psychiatry. 2008;65(10):
13 Management of Pediatric Bipolar Disorder
14 Treatment of Early-Age Mania Study (TEAM Study) 279 youths, ages 6 to 15 BD-I, Manic or Mixed Risperidone n = 89 Lithium n = 90 Divalproex n = 100 Geller B, et al. Arch Gen Psychiatry. 2012;69(5):
15 TEAM Study: Clinical Global Improvement at 8 weeks 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Responder3(CGIFIM3=3Much/Very3Much3Improved) 68.5% 35.6% 24.0% Risperidone3(n3=389) Lithium3(n3=390) Divalproex3(n3=3100) Intent to treat: dropout = nonresponder Risperidone vs lithium: p <.001; Risperidone vs. Divalproex: p <.001; Lithium vs. Divalproex: p =.20 Geller B, et al. Arch Gen Psychiatry. 2012;69(5):
16 FDA Approved Medications for Pediatric Bipolar I Disorder, Mixed or Manic Medication Approved Age Range (y) Asenapine Aripiprazole Olanzapine Quetiapine Risperidone Lithium Source: PI for asenapine; PI for aripiprazole; PI for olanzapine; PI for quetiapine; PI for risperidone; PI for lithium. Drugs@FDA Website:
17 Child and Family-Focused Cognitive-Behavioral Therapy for Pediatric Bipolar Disorder Main Ingredients R A I N B O W Establish Routine Affect regulation I can do it (Positive thinking) No negative thoughts (Reframing thoughts) Be a good friend (Positive social interaction) Oh, how do we solve this problem (Problem solving, Communication) Ways to find social support CFF-CBT, child and family-focused cognitive-behavioral therapy West AE, et al. J Can Acad Child Adolesc Psychiatry. 2009;18(3):
18 #CHAIR2016 Questions Answers &
19 #CHAIR2016 Supplemental Slides
20 Complete Presentation
21 #CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by
22 Pediatric Bipolar Disorder: Diagnosis and Management Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston, TX
23 Karen Dineen Wagner, MD, PhD Disclosures (Past 12 Months) Honoraria: UBM Medica LLC; American Society of Clinical Psychopharmacology (ASCP)
24 #CHAIR2016 Learning Objective 1 Review the genetics and lifetime prevalence of pediatric bipolar disorder
25 #CHAIR2016 Learning Objective 2 Discuss the DSM-5 criteria for pediatric bipolar disorder
26 #CHAIR2016 Learning Objective 3 Describe the FDA approved medications for the treatment of pediatric bipolar I disorder, mixed or manic
27 Off-Label Use Medications discussed in this presentation are off-label for the treatment of bipolar I disorder, manic or mixed episodes in youth, with the exception of lithium, aripiprazole, quetiapine, risperidone, olanzapine and asenapine.
28 Lifetime Prevalence of Adolescent Bipolar Disorder National Comorbidity Survey Adolescent Supplement Face-to-face study of 10,123 US adolescents, years Modified Version of World Health Organization Composite International Diagnostic Interview Sex Age Severe Impairment Total Female % Male % % Bipolar I or II Disorder Merikangas KR et al. JAACAP. 2010;49:
29 Risk of Offspring with Bipolar Disorder No Parent n = 2,239,553 Number of Parents with Bipolar Disorder 1 Parent n = 11,995 2 Parents n = 83 Risk of BD in Offspring (Offspring n = 1,080,030) 0.48% (Offspring n = 23,152) 4.4% (Offspring n = 146) 24.9% National register based cohort study in Denmark Gottesman II, et al. Arch Gen Psychiatry. 2010;67(3):
30 Mood Disorder Questionnaire- Adolescent Version (MDQ-A) Screening Criteria 5/13 Symptoms from Question 1 1. Has there ever been a time for a week or more when your adolescent was not his/her usual self and YES NO felt too good or excited? was so irritable that he/she started fights or arguments with people? felt he/she could do anything? needed much less sleep? couldn t slow his/her mind down or thoughts raced through his/her head? was so easily distracted by things? had much more energy than usual? was much more active or did more things than usual? Wagner KD et al. J Clin Psychiatry. 2006;67(5):
31 Mood Disorder Questionnaire- Adolescent Version (continued) had many boyfriends or girlfriends at the same time? Yes on Question 2 was more interested in sex than usual? did many things that were foolish or risky? spent too much money? used more alcohol or drugs? 2. If you checked YES to more than one of the above, have several of these ever happened to your adolescent during the same period of time? Moderate or Serious on Question 3 3. How much of problems did any of these cause your adolescent like school problems, failing grades, problems with family and friends, legal troubles? Please circle one response only. No problem Minor problem Moderate problem Serious problem Wagner KD et al. J Clin Psychiatry. 2006;67(5):
32 Bipolar I Disorder DSM-5 Criteria Manic Episode Elevated, expansive, irritable mood for 1 week (any duration if hospitalized) AND Increased goal-directed activity or energy Three or more symptoms (four if mood is only irritable) Inflated self esteem, grandiosity Decreased need for sleep Talkative, pressured speech Flight of ideas, racing thoughts Distractibility Impairment or hospitalization American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed
33 Comorbid Disorders Associated with Bipolar Disorder in Children and Adolescents Estimated Prevalence, % ADHD Substance abuse 2, Anxiety disorder 3-9, Obsessive compulsive disorder 4 Panic 5 Generalized anxiety disorder 6 Social anxiety 7 PTSD 8 2 anxiety disorders 9 Oppositional defiant disorder 10,11 75 Conduct disorder 10, Soutullo CA, et al. J Affect Disord. 2002;70(3): ; 2. West SA, et al. Biol Psychiatry. 1996;39(6): ; 3. Geller B, et al. J Child Adolesc Psychopharmacol. 2000;10(3): ; 4. Wilens TE, et al. J Am Acad Child Adolesc Psychiatry. 1999;38(6): ; 5. Masi G, et al. Can J Psychiatry. 2001;46(9): ; 6. Birmaher B, et al. J Clin Psychiatry. 2002;63(5): ; 7. Jerrell JM, et al. Bipolar Disord. 2004;6(4): ; 8. Carlson GA, et al. J Affect Disord. 1998;51(2): ; 9. Kovacs M, et al. J Am Acad Child Adolesc Psychiatry. 1995;34(6): ; 10. Masi G, et al. Biol Psychiatry. 2006;59(7): ; 11. Sala R, et al. J Clin Psychiatry. 2010; 71: ; 12. Goldstein BI, et al. J Am Acad Child Adolesc Psychiatry. 2013;52:
34 Pediatric Bipolar Disorder and Suicidality Weighted Mean Prevalence Suicidal Ideation % Suicide Attempts % Past Current Review of 14 Studies (n = 1595) reporting suicidality and pediatric bipolar disorder Hauser M, et al. Bipolar Disorders. 2013;15(5):
35 8-Year Follow-up of Children with Bipolar I Disorder Cumulative*Frequency*of* Recovery*from*First*Manic* Episode Baseline: N = 115 children, mean age Follow%Up((years) Geller B, et al. Arch Gen Psychiatry. 2008;65(10): Recovery Rate 88%
36 Eight Year Follow-up of Children with Bipolar I Disorder By young adulthood: 44% had manic episodes 20% had depressive episodes 35% had substance use disorders Geller B, et al. Arch Gen Psychiatry. 2008;65(10):
37 FDA Approved Medications for Pediatric Bipolar I Disorder, Mixed or Manic Medication Approved Age Range (y) Asenapine Aripiprazole Olanzapine Quetiapine Risperidone Lithium Source: PI for asenapine; PI for aripiprazole; PI for olanzapine; PI for quetiapine; PI for risperidone; PI for lithium. Drugs@FDA Website:
38 FDA Approved Medications for Pediatric Bipolar I Depression Medication Approved Age Range (y) Olanzapine / Fluoxetine Medications FDA approved for bipolar I depression in adults: Olanzapine/fluoxetine Quetiapine Lurasidone (currently in clinical trial for pediatric bipolar I depression (10-17) Source: PI for olanzapine/fluoxetine Drugs@FDA Website:
39 Example of Controlled Trial of Atypical Antipsychotic for Pediatric Bipolar I Disorder Mean Change in YMRS Score 0!2!4!6!8!10!12!14!16!18 * ** ** RIS+0.5! 2.5mg/day RIS+3!6mg/day Placebo!20 0 Baseline Week 169 youths, ages 10 to 17 years old, with Bipolar I Disorder, manic or mixed episodes; *p <.01; **p <.001; ***p =.002 Haas M, et al. Bipolar Disorders. 2009;11(7): Percentage Response Rate ** ***
40 Response Rates for Second Generation Antipsychotics ( 50% reduction in YMRS) 45 65% YMRS, Young Mania Rating Scale Tohen, et al. Am J Psychiatry. 2007;164(10): ; DelBello, et al. Presented at AACAP 2007 Annual Meeting, Boston MA; Findling RL, et al. J Clin Psychiatry. 2009;70(10): ; Hass M, et al. Bipolar Disorders. 2009;11(5):
41 Lithium for Bipolar I Disorder, Mixed or Manic in Youth (7-17 years) Change in YMRS Lithium (Mean Level 0.98mEq/L) (n = 51) Placebo (n = 28) * * -30 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Adverse events: Significant increase in thyrotropin concentration; (3.0 miu/l); *p <.05 Findling RL, et al. Pediatrics. 2015;136(5):
42 Negative* Controlled Multicenter Trials for Pediatric Bipolar I Disorder, Manic or Mixed Medication Number of Subjects Age Range (years) Mean Dose (mg/day) Study Duration (weeks) Divalproex ER (80 µg/l) 4 Oxcarbazepine Topiramate *No statistically significant difference between medication and placebo on change in Young Mania Rating Scale from baseline to endpoint ER, extended release 1. Wagner KD, et al. J Am Acad Child Adolesc Psychiatry. 2009;48(5): ; 2. Wagner, et al. Am J Psychiatry. 2006;163(7): ; 3. DelBello MP, et al. J Am Acad Child Adolesc Psychiatry. 2005;44(6):
43 Treatment of Early-Age Mania Study (TEAM Study) 279 youths, ages 6 to 15 BD-I, Manic or Mixed Risperidone n = 89 Lithium n = 90 Divalproex n = 100 Geller B, et al. Arch Gen Psychiatry. 2012;69(5):
44 TEAM Study: Dose/Blood Levels Week 1 Week 2 Week 3 Week 4 Week 6 Week 8 Lithium level Mean ± SD; meq/l Valproate level Mean ± SD; μg/ml 0.5 ± ± ± ± ± ± ± ± ± ± ± ± 27 Mean dose/level at endpoint (± SD) Risperidone: 2.6 ± 1.2 mg / day Lithium: 1.1 ± 0.3 meq/l Divalproex: 114 ± 23 μg/ml Adherence (pill count) 95% Geller B, et al. Arch Gen Psychiatry. 2012;69(5):
45 TEAM Study: Clinical Global Improvement at 8 weeks 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Responder3(CGIFIM3=3Much/Very3Much3Improved) 68.5% 35.6% 24.0% Risperidone3(n3=389) Lithium3(n3=390) Divalproex3(n3=3100) Intent to treat: dropout = nonresponder Risperidone vs lithium: p <.001; Risperidone vs. Divalproex: p <.001; Lithium vs. Divalproex: p =.20 Geller B, et al. Arch Gen Psychiatry. 2012;69(5):
46 Treatment Duration Minimum of 4 to 6 weeks for each medication trial At therapeutic blood levels and/or adequate dose Consider tapering medication after sustained remission of at least 12 to 24 consecutive months Kowatch, RA et al. J Am Acad Child Adolesc Psychiatry. 2005;44(3):
47 Safety Issues Regarding Treatment of Pediatric Bipolar Disorder Weight gain Diabetes Metabolic syndrome Cognitive dullness Hyperprolactinemia Polycystic ovarian syndrome Hypothyroidism Pancreatitis Abnormal involuntary movements Neuroleptic malignant syndrome Kowatch RA, et al. J Am Acad Child Adolesc Psychiatry. 2005;44(3):
48 Cardiometabolic Risk of Atypical Antipsychotics 338 antipsychotic naïve youth, who received atypical antipsychotics over a 12-week period Medication Mean Weight Gain, kg Olanzapine 8.5 Quetiapine 6.1 Risperidone 5.3 Aripiprazole 4.4 Untreated Group 0.2 Correll CU, et al. JAMA. 2009;302(16):
49 Cardiometabolic Risk of Atypical Antipsychotics Medication Total Cholesterol Triglycerides Highlighted numbers in yellow are significant at p <.05 Correll CU, et al. JAMA. 2009;302(16): Metabolic Non-HDL Ratio of Triglycerides to HDL Olanzapine Quetiapine Risperidone Aripiprazole
50 Antipsychotics and Type 2 Diabetes in Youth Retrospective cohort study of 25,858 youth in Tennessee Medicaid who initiated antipsychotics compared to control group who initiated another psychotropic Probability of Type 2 Diabetes Years of Follow-Up Bobo WV, et al. JAMA Psychiatry. 2013;70(10): Type 2 Diabetes per 10,000 Person-Years Control <5 g 5-99 g 100 g Cumulative Antipsychotic Dose, Chlorpromazine Equivalents
51 Risperidone Discontinuation and Cardiometabolic Outcomes 101 patients ages 7 to 17 treated with risperidone for 36 months Follow-up 1.5 years Outcome Discontinuation of antipsychotic reversed weight gain and improved cardiometabolic parameters Calarge CA, et al. J Child Adolesc Psychopharmacol. 2014; 24(3):
52 Strategies for Prevention and Management of Weight Gain Healthy lifestyle behaviors 12-item list related to eating habits and exercise Correll CU, et al. J Am Acad Child Adolesc Psychiatry. 2006;45(7):
53 Controlled Trial of Flax Oil in Pediatric Bipolar Disorder 51 youths (ages 6 to 17 years) with BD-I or BD-II Randomized to flax oil capsules (omega-3 fatty acids α-linolenic acid) or olive oil placebo adjunctively or as monotherapy Doses titrated to 12 capsules per day over 16 weeks Results: No significant differences between flax oil and placebo groups on change in mania (YMRS), depression (CDRS-R) and Clinical Global Impression ratings YMRS, Young Mania Rating Scale; CDRS-R, Child Depression Rating Scale-Revised Gracious BL, et al. Bipolar Disord. 2010;12(2):
54 Multinutrient Supplement for Pediatric Bipolar Spectrum Disorders 10 children (6-12 yrs) received a 36 ingredient multinutrient supplement, EM-Powerplus (EMP+) for bipolar spectrum disorder. Contains minerals, vitamins, amino acids and antioxidants Dosage 1 capsule t.i.d. to 5 capsules t.i.d. Outcome 70% completed study Four serum vitamin concentrations increased; Vitamin A-retinol, vitamin B6, Vitamin E-α tocopherol, folate Over 8 weeks 37% decrease in depression scores 45% decrease in mania scores Adverse events: insomnia, gastrointestinal upset Frazier EA, et al. J Alternative and Complementary Medicine. 2012;18(7): ; Frazier EA, et al. J Child and Adolsc Psychopharm. 2013;23(8):
55 Intranasal Ketamine for Pediatric Bipolar Disorder Retrospective chart review of 12 youth ages 6 to 19 years with treatment refractory bipolar I disorder Received intranasal ketamine* doses mg, administered at intervals of 3-7 days Therapeutic benefit within 1-24 hours; lasted hours Improvement in mania, anxiety, aggression Most common adverse events Dizziness, elated mood, spaced out *Not FDA approved for bipolar disorder Papolos DF, et al. J Affect Dis. 2013;147:
56 Child and Family-Focused Cognitive-Behavioral Therapy for Pediatric Bipolar Disorder Main Ingredients R A I N B O W Establish Routine Affect regulation I can do it (Positive thinking) No negative thoughts (Reframing thoughts) Be a good friend (Positive social interaction) Oh, how do we solve this problem (Problem solving, Communication) Ways to find social support CFF-CBT, child and family-focused cognitive-behavioral therapy West AE, et al. J Can Acad Child Adolesc Psychiatry. 2009;18(3):
57 #CHAIR2016 Questions Answers &
Bipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationComprehensive Quick Reference Handout on Pediatric Bipolar Disorder By Jessica Tomasula
Comprehensive Quick Reference Handout on Pediatric Bipolar Disorder By Jessica Tomasula Official Name Bipolar Disorder; also referred to as Manic Depression Definitions (DSM-IV-TR, 2000) Bipolar I Disorder
More information#CHAIR2016. September 16 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 16 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Depression in Children and Adolescents Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston, TX Karen Dineen
More informationD I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment.
Dr. Crismon has no potential conflicts of interest to disclose with regard to this presentation. M. Lynn Crismon, Pharm.D., FCCP, BCPP Dean James T. Doluisio Regents Chair & Behrens Centennial Professor
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationPractice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,
Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationPediatric Bipolar Disorder: Advances in Diagnosis and Research
Pediatric Bipolar Disorder: Advances in Diagnosis and Research Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts
More informationTreatment of Bipolar Disorder in Youth
Treatment of Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital
More informationPediatric Bipolar Disorder and ADHD
Pediatric Bipolar Disorder and ADHD Janet Wozniak, M.D. Director, Pediatric Bipolar Disorder Research Program Associate Professor Psychiatry Massachusetts General Hospital Harvard Medical School Disclosures
More informationKelly Godecke, MD Department of Psychiatry University of Utah
Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar
More informationNOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression)
NOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression) 11 APRIL 2013 Josephine Cucchiaro, PhD Vice President Clinical Operations & Project Management Sunovion Pharmaceuticals
More informationForty-Eighth Annual Teaching Conference Pediatrics for the Practitioner -UT Health Science Center San Antonio School of Medicine June 10-12, 2011
Adelaide Robb, MD Associate Professor Psychiatry and Pediatrics Source Advisory Board Disclosure Speaker s Bureau Bristol Myers Squibb Yes Yes Yes Epocrates Research Contract Royalties Yes Stock Janssen
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationBIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences BIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD PROFESSOR DEPARTMENT OF PSYCHIATRY UNIVERSITY
More informationBipolar disorder and severe irritability in youth: Diagnosis and treatment. Ellen Leibenluft, M.D.
Bipolar disorder and severe irritability in youth: Diagnosis and treatment Ellen Leibenluft, M.D. Chief, Section on Bipolar Spectrum Disorders Emotion and Development Branch National Institute of Mental
More informationSevere Mood Dysregulation in Children and Adolescents Research Findings Support Diagnostic Validity of Pediatric Bipolar Disorder
Severe Mood Dysregulation in Children and Adolescents Research Findings Support Diagnostic Validity of Pediatric Bipolar Disorder Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric
More informationCASE 5 - Toy & Klamen CASE FILES: Psychiatry
CASE 5 - Toy & Klamen CASE FILES: Psychiatry A 14-year-old boy is brought to the emergency department after being found in the basement of his home by his parents during the middle of a school day. The
More informationBipolar Disorder Demystified. Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry
Bipolar Disorder Demystified Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry Underdiagnoses of Depression In Primary Care 2005 Study of 650 primary care patients on antidepressants
More informationBipolar Disorders. Disclosure Statement. I have no financial disclosures or conflicts of interest
Bipolar Disorders Ahsan Naseem, MD Diplomate American Board of Psychiatry and Neurology Adult and Geriatric Psychiatry Medical Director Bryan Heartland Psychiatry Bryan Physician Network Partner Cheney
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX
A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,
More informationTreatment of Anxiety and Mood Disorders. John T. Walkup, MD Division of Child and Adolescent Psychiatry Weill Cornell Medical College New York, NY
Treatment of Anxiety and Mood Disorders John T. Walkup, MD Division of Child and Adolescent Psychiatry Weill Cornell Medical College New York, NY Disclosure: John T. Walkup, MD Consultant Advisory Board
More informationAggression (Severe) in Children under Age 6
Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationPEDIATRIC BIPOLAR DISORDER
PEDIATRIC BIPOLAR DISORDER Swapna Deshpande, MD Clinical Assistant Professor Associate Training Director, Child/Adolescent Fellowship Program Department of Psychiatry & Behavioral Sciences University of
More informationMood Disorders for Care Coordinators
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/054. (For National Authority Use Only) Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex Sodium Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationPDF created with pdffactory Pro trial version
با ی د ر ا ر وه روا ز ش ی دا ه ع وم ش ی ا ان Treatment Challenges in BD Major depressive episode Mixed states= 20% Rapid cycling= 18% (annually), 31.5% (lifetime) Psychiatric Comorbidity (substance abuse,
More informationBipolar Disorder in Child Psychiatric Practice: A Case Report
CASE REPORT Bipolar Disorder in Child Psychiatric Practice: A Case Report 1. 2, 2, * A. Tsarkov *, P. Petlovanyi 1 Chainama Hills College Hospital, Lusaka, Zambia 2 Department of Psychiatry, School of
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationJuvenile Depression.
Juvenile Depression Karen Dineen Wagner, MD, PhD Titus Harris Chair Professor and Chair Department of Psychiatry & Behavioral Sciences University of Texas Medical Branch Galveston, Texas Disclosure (Past
More informationBIPOLAR DISORDER AND ADHD IN CHILDREN
BIPOLAR DISORDER AND ADHD IN CHILDREN BIPOLAR I DISORDER IS BEING DIAGNOSED WITH INCREASING FREQUENCY (INTENSITY) IN PRE-PUBERTAL CHIDREN WITH THE CAVEAT (WARNING / STIPULATION) THAT CLASSIC MANIC EPISODES
More informationThe Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients with Bipolar Disorder
Zahedan Journal of Research in Medical Sciences Journal homepage: www.zjrms.ir The Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients
More informationDepression Management
Depression Management Ulka Agarwal, M.D. Adjunct Psychiatrist Pine Rest Christian Mental Health Disclosures The presenter and all planners of this education activity do not have a financial/arrangement
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationKelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric
More informationLithium in bipolar disorders.
Lithium in bipolar disorders. S. Mehdi Samimi Ardestani M.D. Department of Psychiatry, Shahid Beheshti University of Medical Science, Behavioral science research center Iranian psychiatric association,
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationBipolar Disorder 4/6/2014. Bipolar Disorder. Symptoms of Depression. Mania. Depression
Bipolar Disorder J. H. Atkinson, M.D. Professor of Psychiatry HIV Neurobehavioral Research Programs University of California, San Diego KETHEA, Athens Slides courtesy of John Kelsoe, M.D. Bipolar Disorder
More informationTreatment of Bipolar disorder
8/6/215 Treatment of Bipolar disorder Pichai Ittasakul, M.D. Department of Psychiatry, Ramathibodi Hospital, Mahidol University Bipolar disorder Manic-depressive Illness. is characterized by the occurrence
More informationChallenges in identifying and treating bipolar depression: a guide
Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationPATIENT NAME: DATE OF DISCHARGE: DISCHARGE SURVEY
PATIENT NAME: DATE OF DISCHARGE: DISCHARGE SURVEY Please indicate whether you feel Living Hope Eating Disorder Treatment Center provided either Satisfactory or Unsatisfactory service for each number listed
More informationHandout for the Neuroscience Education Institute (NEI) online activity: Juvenile Bipolar Disorder: Further Complicated by Comorbidity
Handout for the Neuroscience Education Institute (NEI) online activity: Juvenile Bipolar Disorder: Further Complicated by Comorbidity Learning Objectives Utilize evidence-based strategies to accurately
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: AZ.CP.PHAR.10.11.8 Effective Date: 07.2016 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy
More informationBipolar Disorder Michael Coudreaut, MD
Bipolar Disorder Michael Coudreaut, MD Consultation liaison psychiatry at Intermountain Medical Center; Adjuctive assistant professor, Departments of psychiaitry, University of Utah; Salt Lake City, Utah
More informationThe Bipolar Depression Bulletin
The Bipolar Depression Bulletin Bipolar Depression in Pediatric Patients Sponsored by Sunovion Pharmaceuticals Inc. Please see Important Safety Information, including BOXED WARNING, on page 13 INDICATIONS
More informationEmpirical Evidence for the Use of Lithium and Anticonvulsants in Children with Psychiatric Disorders
REVIEW Empirical Evidence for the Use of Lithium and Anticonvulsants in Children with Psychiatric Disorders Melissa Lopez-Larson, MD, and Jean A. Frazier, MD Background: The use of psychotropic medications
More informationMOOD (AFFECTIVE) DISORDERS and ANXIETY DISORDERS
MOOD (AFFECTIVE) DISORDERS and ANXIETY DISORDERS Shelley Klipp AS91 Spring 2010 TIP 42 Pages 226-231 and 369-379 DSM IV-TR APA 2000 Co-Occurring Substance Abuse and Mental Disorders by John Smith Types
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Single Technology Appraisal Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 November 2011 SYCREST 5 mg, sublingual tablet B/60 (CIP code: 415 241-6) B/100 (CIP code: 579 353-1) SYCREST 10
More informationDisclosure Statement. A Rational Approach to Psychopharmacology. Goals 10/28/2013
A Rational Approach to Psychopharmacology Disclosure Statement Full time employed physician with MaineGeneral Medical Center in Waterville and Augusta No conflicts of interest to disclose Goals Promote
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Best Practices in the Management of Bipolar Disorder Robert M. A. Hirschfeld, MD University of Texas Medical Branch Galveston, TX Peter
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Bipolare Disorder Initial Evaliaton and Referral Criteria
More informationTable of Contents. 1.0 Policy Statement...1
Division of Medical Assistance General Clinical Policy No. A-6 Table of Contents 1.0 Policy Statement...1 2.0 Policy Guidelines...1 2.1 Eligible Recipients...1 2.1.1 General Provisions...1 2.1.2 EPSDT
More informationUpdate on Pediatric Bipolar Disorder
Update on Pediatric Bipolar Disorder Benjamin I. Goldstein, MD,, FRCPC Associate Professor Departments of Psychiatry & Pharmacology Sunnybrook Health Sciences Centre University of Toronto Faculty of Medicine
More informationWhat s New in Psychotropic Prescribing for Children: Trends, Guidelines & Practice
3 rd Annual Challenges & Innovations in Rural Psychiatry Conference What s New in Psychotropic Prescribing for Children: Trends, Guidelines & Practice June 22, 2016 What s New in Psychotropic Prescribing
More informationContemporary Psychiatric-Mental Health Nursing Third Edition. Introduction. Introduction 9/10/ % of US suffers from Mood Disorders
Contemporary Psychiatric-Mental Health Nursing Third Edition CHAPTER 17 Mood Disorders Introduction 12% of US suffers from Mood Disorders MD are a group of psychiatric DO characterized by physical, emotional
More information2013 Virtual AD/HD Conference 1
Medication for & Coexisting Conditions Part 2 Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationBipolar Network News Free
Bipolar Network News Free Published since 1995 The latest news on bipolar disorder research from around the world bipolarnews.org Updates from the 2012 Meeting of the American Academy of Child and Adolescent
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationAffective Disorders.
Affective Disorders http://www.bristol.ac.uk/medicalschool/hippocrates/psychethics/ Affective Disorders Depression Mania / Hypomania Bipolar mood disorder Recurrent depression Persistent mood disorders
More informationPediatric Bipolar Disorder and ASD
Pediatric Bipolar Disorder and ASD Janet Wozniak, MD Associate Professor of Psychiatry Massachusetts General Hospital Disclosures My spouse/partner and I have the following relevant financial relationship
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationN e w s R e l e a s e
Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 N e w s R e l e a s e Contact: Patrick Gaffey Senior Director, Corporate Communications Sunovion Pharmaceuticals
More informationObjectives. Disclosure of Commercial Support. Psychopharmacology and Pediatric Obesity
Psychopharmacology and Pediatric Obesity Raise awareness of the complex interplay between mental illness and obesity/metabolic disturbances in children Dina Panagiotopoulos, MD, FRCPC Clinical Professor
More informationAPPENDIX 27: INTERVENTIONS FOR CHILDREN AND YOUNG PEOPLE STUDY CHARACTERISTICS
APPEDIX 27: ITERVETIOS FOR CHILDRE AD YOUG PEOPLE STUDY CHARACTERISTICS 1.1 Pharmacological interventions... 2 1.2 Psychological interventions... 6 1.3 utritional interventions... 6 Abbreviations BRA ChIPS
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationBipolar Depression: Engaging the Patient. Mark Frye, MD Mayo Clinic Rochester, MN
Bipolar Depression: Engaging the Patient Mark Frye, MD Mayo Clinic Rochester, MN Mark Frye, MD Disclosures Research/Grants: AssureRX Health Inc.; Janssen Research & Development, LLC; Mayo Foundation for
More informationBrief Notes on the Mental Health of Children and Adolescents
Brief Notes on the Mental Health of Children and Adolescents The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.59 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at the
More informationApproach to Bipolar Disorder Family Medicine Forum November 14 17, 2018 Toronto, Ontario
Approach to Bipolar Disorder Family Medicine Forum November 14 17, 2018 Toronto, Ontario Jon Davine, MD, CCFP, FRCP(C) Associate Professor, McMaster University Faculty/Presenter Disclosure Faculty: Dr.
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationJonathan Haverkampf BIPOLAR DISORDR BIPOLAR DISORDER. Dr. Jonathan Haverkampf, M.D.
BIPOLAR DISORDER Dr., M.D. Abstract - Bipolar disorder is a condition affecting an individual s affective states (mood). The different flavors of bipolar disorder have in common that there are alterations
More informationPsychotropic Medication Management in Children and Adolescents
Drug Use Research & Management Program DHS Division of Medical Assistance Programs, 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Psychotropic Medication Management
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationPediatrics Grand Rounds 5 March University of Texas Health Science Center at San Antonio I-1
Diagnosis and Treatment of Depression in Children and Adolescents Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department of Psychiatry The Disclosures
More informationCardiometabolic Risk Factors and Antipsychotic Medications Changing Prescribing Practices Promoting Wellness
Cardiometabolic Risk Factors and Antipsychotic Medications Changing Prescribing Practices Promoting Wellness Sally Ricketts, M.D. New York State Office of Mental Health Bureau of Evidence-Based Services
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationA Closer Look: NH Primary Care Clinician Perspective on Caring for Pediatric Patients with ADHD
A Closer Look: NH Primary Care Clinician Perspective on Caring for Pediatric Patients with ADHD W. Burleson Daviss, MD Dept. of Psychiatry / DHMC Molly O Neil University of New Hampshire Objectives 1)
More informationHelping a friend or loved one manage bipolar depression.
each month for up to 12 prescriptions Helping a friend or loved one manage bipolar depression. Please see Important Safety Information, including Boxed Warnings, on pages 18-21, and #1 Prescribed Branded
More informationFixing the Mix-Up Over Mixed Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Fixing the Mix-Up Over Mixed Depression Diagnosing and Treating DSM-5 Defined Mixed Features in Mood Disorders Learning Objectives
More informationApril 2016 Prepared By: Kimberly D. Griego, PharmD, CGP
April 2016 Prepared By: Kimberly D. Griego, PharmD, CGP Bipolar disorder (BD), also referred to as manic-depression, presents with dramatic swings in a person s mood and energy level, which affects their
More informationFile NDA SE5 046/047, NDA SE5 036/037, NDA SE5 020/021
M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: 18 June 2007 FROM: TO: SUBJECT: Mitchell V.
More informationEfficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study
NEW RESEARCH Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study Melissa P. DelBello, MD, MS, Robert Goldman, PhD, Debra Phillips,
More informationCriteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents
Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents DRUG NAME INDICATIONS / ACCEPTABLE USES PRIOR STIMULANT/ADHD DRUGS Daytrana (methylphenidate) ADHD
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More information